Small molecule ectonucleotide pyrophosphatase/phosphodiesterase 1 inhibitors in cancer immunotherapy for harnessing innate immunity

被引：5
|
作者：
Choi, Junwon [1 ]
机构：
[1] Ajou Univ, Dept Mol Sci & Technol, Suwon, Gyeonggi, South Korea
来源：
BULLETIN OF THE KOREAN CHEMICAL SOCIETY | 2023年 / 44卷 / 02期
基金：
新加坡国家研究基金会;
关键词：
cancer immunotherapy; cGAMP; ENPP1; inhibitor; innate immunity; STING; CYCLIC GMP-AMP; NUCLEOTIDE PYROPHOSPHATASE; EXTRACELLULAR CGAMP; POTENT INHIBITORS; BYSTANDER CELLS; HUMAN NPP1; DERIVATIVES; HYDROLYSIS; 2ND-MESSENGER; ENPP1;
D O I：
10.1002/bkcs.12646
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) was recently identified as a major hydrolase of an endogenous stimulator of interferon genes (STING) agonist, 2 ',3 '-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP). ENPP1 is a promising therapeutic target in cancer immunotherapy, in which the inhibition of ENPP1 enhances anticancer immunity via STING-mediated innate immune activation. This review highlights the role of ENPP1 in innate immunity and the recent discovery of small molecule ENPP1 inhibitors as immunomodulators in cancer immunotherapy.
引用
收藏
页码：88 / 99
页数：12
相关论文
共 50 条
  • [21] Highly Potent and Selective Ectonucleotide Pyrophosphatase/Phosphodiesterase I Inhibitors Based on an Adenosine 5′-(α or γ)-Thio-(α,β- or β,γ)-methylenetriphosphate Scaffold
    Nadel, Yael
    Lecka, Joanna
    Gilad, Yocheved
    Ben-David, Gal
    Foerster, Daniel
    Reiser, Georg
    Kenigsberg, Sarah
    Camden, Jean
    Weisman, Gary A.
    Senderowitz, Hanoch
    Sevigny, Jean
    Fischer, Bilha
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (11) : 4677 - 4691
  • [22] Exploiting innate immunity for cancer immunotherapy
    Yi, Ming
    Li, Tianye
    Niu, Mengke
    Mei, Qi
    Zhao, Bin
    Chu, Qian
    Dai, Zhijun
    Wu, Kongming
    MOLECULAR CANCER, 2023, 22 (01)
  • [23] Cancer immunotherapy targeting innate immunity
    Ma, Zhifeng
    Li, Wen
    Hata, Masaki
    El-Darawish, Yosif
    Yamanishi, Kyosuke
    Yamanishi, Hiromichi
    Tanaka, Yoshimasa
    Okamura, Haruki
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2016, 38 : S73 - S73
  • [24] Immunotherapy for cancer: promoting innate immunity
    Lotfi, Ramin
    Schrezenmeier, Hubert
    Lotze, Michael Thomas
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2009, 14 : 818 - 832
  • [25] Exploiting innate immunity for cancer immunotherapy
    Ming Yi
    Tianye Li
    Mengke Niu
    Qi Mei
    Bin Zhao
    Qian Chu
    Zhijun Dai
    Kongming Wu
    Molecular Cancer, 22
  • [26] Development of Novel Ecto-Nucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Inhibitors for Tumor Immunotherapy
    Wang, Xiang
    Lu, Xing
    Yan, Daojing
    Zhou, Yajun
    Tan, Xiangshi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (13)
  • [27] Editorial: Immunotherapy and small molecule inhibitors as combinational cancer therapeutics
    Khan, Mohd Wajid Ali
    Aziz, Mohammad Azhar
    Rajendrasozhan, Saravanan
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [28] Small molecule T-reg inhibitors for cancer immunotherapy
    Kumar, Suresh
    Wu, Jian
    Wang, Liquing
    Wang, Feng
    Kodrasov, Matthew P.
    Agarwal, Saket
    Sokirniy, Ivan
    Yeckley, Thomas
    Weinstock, Joseph
    Matten, Michael R.
    Hancock, Wayne W.
    CANCER RESEARCH, 2016, 76
  • [29] Publisher Correction: Harnessing innate immunity in cancer therapy
    Olivier Demaria
    Stéphanie Cornen
    Marc Daëron
    Yannis Morel
    Ruslan Medzhitov
    Eric Vivier
    Nature, 2019, 576 (7785) : E3 - E3
  • [30] The role of membrane glycoprotein plasma cell antigen 1 ectonucleotide pyrophosphatase phosphodiesterase 1 in the pathogenesis of insulin resistance and related abnormalities
    Goldfine, Ira D.
    Maddux, Betty A.
    Youngren, Jack F.
    Reaven, Gerald
    Accili, Domenico
    Trischitta, Vincenzo
    Vigneri, Riccardo
    Frittitta, Lucia
    ENDOCRINE REVIEWS, 2008, 29 (01) : 62 - 75
12345